{"disease":{"id":"hereditary-angioedema-hae","name":"hereditary angioedema hae"},"drugs":{"marketed":[{"drug_id":"donidalorsen","indication_name":"hereditary angioedema (HAE)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Dawnzera","generic_name":"DONIDALORSEN","company_name":"Ionis Pharms Inc","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":47,"revenue":null,"mechanism":"Dawnzera works by binding to a specific messenger RNA molecule to prevent the production of a faulty protein that causes hereditary angioedema."},{"drug_id":"donidalorsen","indication_name":"hereditary angioedema (HAE)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Dawnzera","generic_name":"DONIDALORSEN","company_name":"Ionis Pharms Inc","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":47,"revenue":null,"mechanism":"Dawnzera works by binding to a specific messenger RNA molecule to prevent the production of a faulty protein that causes hereditary angioedema."},{"drug_id":"sebetralstat","indication_name":"hereditary angioedema (HAE)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ekterly","generic_name":"SEBETRALSTAT","company_name":"Kalvista","drug_phase":"marketed","molecular_target":"","drug_class":"Plasma Kallikrein Inhibitor [EPC]","quality_score":45,"revenue":null,"mechanism":"Ekterly works by blocking the plasma kallikrein enzyme, which is involved in the production of bradykinin, a key mediator of HAE symptoms."}],"pipeline":[],"offLabel":[],"totalMarketed":3,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT01034969","title":"Firazyr® Patient Registry (Icatibant Outcome Survey - IOS)","phase":"","overall_status":"COMPLETED","enrollment_count":1761,"lead_sponsor_name":"Shire","has_results":false},{"nct_id":"NCT07293364","title":"A Study to Learn About the C1-Inhibitor Function as Diagnosis for Hereditary Angioedema","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":514,"lead_sponsor_name":"Takeda","has_results":false},{"nct_id":"NCT03472040","title":"A Long Term Safety Study of BCX7353 in Hereditary Angioedema","phase":"PHASE2, PHASE3","overall_status":"COMPLETED","enrollment_count":387,"lead_sponsor_name":"BioCryst Pharmaceuticals","has_results":true},{"nct_id":"NCT06806618","title":"HAE Burden and Crisis Management","phase":"","overall_status":"RECRUITING","enrollment_count":300,"lead_sponsor_name":"University Hospital, Grenoble","has_results":false},{"nct_id":"NCT02741596","title":"Long-term Safety and Efficacy Study of DX-2930 (SHP643) to Prevent Acute Angioedema Attacks in Patients With Type I and Type II HAE","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":212,"lead_sponsor_name":"Shire","has_results":true},{"nct_id":"NCT04861090","title":"A Study in Teenagers and Adults With Hereditary Angioedema (HAE) Type I or Type II Who Use Lanadelumab as Long-Term Prophylaxis","phase":"","overall_status":"COMPLETED","enrollment_count":207,"lead_sponsor_name":"Takeda","has_results":false},{"nct_id":"NCT04057131","title":"FIRAZYR General Drug Use-Results Survey (Japan)","phase":"","overall_status":"COMPLETED","enrollment_count":179,"lead_sponsor_name":"Shire","has_results":true},{"nct_id":"NCT03845400","title":"A Study of Lanadelumab in Persons With Hereditary Angioedema (HAE) Type I or II in North America","phase":"","overall_status":"COMPLETED","enrollment_count":168,"lead_sponsor_name":"Shire","has_results":false},{"nct_id":"NCT05397431","title":"A Survey of Lanadelumab in Participants With Hereditary Angioedema","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":155,"lead_sponsor_name":"Takeda","has_results":false},{"nct_id":"NCT00456508","title":"Safety and Efficacy Study of Repeated Doses of DX-88 (Ecallantide) to Treat Attacks of Hereditary Angioedema (HAE)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":147,"lead_sponsor_name":"Shire","has_results":true},{"nct_id":"NCT04130191","title":"A Study of Lanadelumab in Persons With Hereditary Angioedema (HAE) Type I or II","phase":"","overall_status":"COMPLETED","enrollment_count":140,"lead_sponsor_name":"Shire","has_results":false},{"nct_id":"NCT02586805","title":"Efficacy and Safety Study of DX-2930 to Prevent Acute Angioedema Attacks in Patients With Type I and Type II HAE","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":125,"lead_sponsor_name":"Shire","has_results":true},{"nct_id":"NCT03485911","title":"Efficacy and Safety Study of BCX7353 as an Oral Treatment for the Prevention of Attacks in HAE","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":121,"lead_sponsor_name":"BioCryst Pharmaceuticals","has_results":true},{"nct_id":"NCT06346899","title":"A Study of Lanadelumab (Takhzyro) and Icatibant (Firazyr®) in Persons With HAE in China","phase":"","overall_status":"COMPLETED","enrollment_count":115,"lead_sponsor_name":"Takeda","has_results":false},{"nct_id":"NCT07218393","title":"A Study About the Diagnosis and Management of Hereditary Angioedema (HAE) in Egypt","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":100,"lead_sponsor_name":"Takeda","has_results":false},{"nct_id":"NCT00457015","title":"Efficacy Study of DX-88 (Ecallantide) to Treat Acute Attacks of Hereditary Angioedema (HAE)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":96,"lead_sponsor_name":"Shire","has_results":true},{"nct_id":"NCT00262080","title":"Efficacy and Safety Study of DX-88 to Treat Acute Attacks of Hereditary Angioedema (HAE)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":91,"lead_sponsor_name":"Shire","has_results":true},{"nct_id":"NCT07428499","title":"Phase 3 Extension Study of ADX-324 in Participants With Hereditary Angioedema (HAE)","phase":"PHASE3","overall_status":"NOT_YET_RECRUITING","enrollment_count":90,"lead_sponsor_name":"ADARx Pharmaceuticals, Inc.","has_results":false},{"nct_id":"NCT06960213","title":"STOP-HAE: A Phase 3 Study of ADX-324 in HAE","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":90,"lead_sponsor_name":"ADARx Pharmaceuticals, Inc.","has_results":false},{"nct_id":"NCT05489640","title":"A Study in Adults With Hereditary Angioedema (HAE) Who Currently Receive Icatibant at Home","phase":"","overall_status":"COMPLETED","enrollment_count":85,"lead_sponsor_name":"Takeda","has_results":false},{"nct_id":"NCT01541423","title":"A European Post-Authorisation Observational Study Of Patients With Hereditary Angioedema","phase":"","overall_status":"COMPLETED","enrollment_count":83,"lead_sponsor_name":"Shire","has_results":false},{"nct_id":"NCT01059526","title":"Observational Safety Study for KALBITOR (Ecallantide) in the Treatment of Acute Attacks of Hereditary Angioedema","phase":"","overall_status":"COMPLETED","enrollment_count":81,"lead_sponsor_name":"Shire","has_results":true},{"nct_id":"NCT01826916","title":"EDEMA2: Evaluation of DX-88's Effect in Mitigating Angioedema","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":77,"lead_sponsor_name":"Shire","has_results":false},{"nct_id":"NCT02584959","title":"Study to Evaluate the Clinical Efficacy and Safety of Subcutaneously Administered C1 Esterase Inhibitor for the Prevention of Angioedema Attacks in Adolescents and Adults With Hereditary Angioedema","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":75,"lead_sponsor_name":"Shire","has_results":true},{"nct_id":"NCT05578417","title":"A Study to Review the Treatment and Outcomes of Teenagers and Adults With Non-histaminergic Angioedema With Normal C1 Inhibitor in Canada","phase":"","overall_status":"COMPLETED","enrollment_count":60,"lead_sponsor_name":"Takeda","has_results":false},{"nct_id":"NCT03240133","title":"Study of BCX7353 as a Treatment for Attacks of Hereditary Angioedema","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":58,"lead_sponsor_name":"BioCryst Pharmaceuticals","has_results":true},{"nct_id":"NCT05469789","title":"A Study of Lanadelumab in Teenagers and Adults With Hereditary Angioedema (HAE)","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":50,"lead_sponsor_name":"Takeda","has_results":false},{"nct_id":"NCT07263685","title":"A Study of Lanadelumab in Teenagers and Adults With Hereditary Angioedema (HAE) in the Kingdom of Saudi Arabia","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":50,"lead_sponsor_name":"Takeda","has_results":false},{"nct_id":"NCT02663687","title":"Phase 1 Study to Assess the Safety, Tolerability, and Pharmacokinetics of Recombinant Human C1 Esterase Inhibitor in Healthy Adult Subjects","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":48,"lead_sponsor_name":"Shire","has_results":true},{"nct_id":"NCT05147181","title":"A Study With Lanadelumab in Persons With Hereditary Angioedema (HAE) in Poland","phase":"","overall_status":"COMPLETED","enrollment_count":48,"lead_sponsor_name":"Takeda","has_results":false},{"nct_id":"NCT01756157","title":"Subcutaneous CINRYZE With Recombinant Human Hyaluronidase for Prevention of Angioedema Attacks","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":47,"lead_sponsor_name":"Shire","has_results":true},{"nct_id":"NCT07251933","title":"A Study of Lanadelumab in Children With Hereditary Angioedema (HAE) in Multiple Countries","phase":"","overall_status":"RECRUITING","enrollment_count":40,"lead_sponsor_name":"Takeda","has_results":false},{"nct_id":"NCT02093923","title":"A Double-Blind, Multiple Ascending Dose Study to Assess Safety, Tolerability and Pharmacokinetics of DX-2930 in Hereditary Angioedema Participants","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":38,"lead_sponsor_name":"Shire","has_results":true},{"nct_id":"NCT07445087","title":"A Study of Takhzyro in Teenagers and Adults With Hereditary Angioedema (HAE) in South Korea","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":35,"lead_sponsor_name":"Takeda","has_results":false},{"nct_id":"NCT01923207","title":"A Single Increasing Dose Study to Assess Safety and Tolerability of DX-2930 in Healthy Subjects","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":32,"lead_sponsor_name":"Shire","has_results":false},{"nct_id":"NCT01386658","title":"A Pharmacokinetic, Tolerability and Safety Study of Icatibant in Children and Adolescents With Hereditary Angioedema","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":32,"lead_sponsor_name":"Shire","has_results":true},{"nct_id":"NCT05509569","title":"A Survey of Icatibant in Pediatric Participants With Hereditary Angioedema","phase":"","overall_status":"COMPLETED","enrollment_count":32,"lead_sponsor_name":"Takeda","has_results":false},{"nct_id":"NCT06846398","title":"A Phase 2 in Adult Subjects With Hereditary Angioedema","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":25,"lead_sponsor_name":"Shanghai Argo Biopharmaceutical Co., Ltd.","has_results":false},{"nct_id":"NCT05819775","title":"CSL312_3003 Safety and Pharmacokinetic Study in Subjects 2 to 11 Years of Age With Hereditary Angioedema","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":22,"lead_sponsor_name":"CSL Behring","has_results":false},{"nct_id":"NCT05460325","title":"A Study of Lanadelumab (SHP643) in Chinese Participants With Hereditary Angioedema (HAE)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":20,"lead_sponsor_name":"Takeda","has_results":true},{"nct_id":"NCT03873116","title":"Study to Evaluate the Efficacy and Safety of BCX7353 as an Oral Treatment for the Prevention of HAE Attacks in Japan","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":19,"lead_sponsor_name":"BioCryst Pharmaceuticals","has_results":true},{"nct_id":"NCT06587464","title":"A Study to Explore Hereditary Angioedema (HAE) Symptoms and Treatment Patterns in Korean People","phase":"","overall_status":"COMPLETED","enrollment_count":19,"lead_sponsor_name":"Takeda","has_results":false},{"nct_id":"NCT02045264","title":"Open-label, Single-arm Study to Assess the Pharmacokinetics, Safety, and Tolerability of a Single Subcutaneous Dose of Icatibant in Healthy Japanese Volunteers","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":12,"lead_sponsor_name":"Shire","has_results":true},{"nct_id":"NCT04180163","title":"Efficacy and Safety of Lanadelumab (SHP643) in Japanese Participants With Hereditary Angioedema (HAE)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":12,"lead_sponsor_name":"Shire","has_results":true},{"nct_id":"NCT02052141","title":"Safety and Efficacy Study of CINRYZE for Prevention of Angioedema Attacks in Children Ages 6-11 With Hereditary Angioedema","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":12,"lead_sponsor_name":"Shire","has_results":true},{"nct_id":"NCT07046806","title":"Oral Deucrictibant for Prophylactic and Acute Treatment in Hereditary Angioedema Patients","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":10,"lead_sponsor_name":"Institute for Asthma and Allergy","has_results":false},{"nct_id":"NCT01095510","title":"CINRYZE for the Treatment of Hereditary Angioedema Attacks in Children Under the Age of 12","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":9,"lead_sponsor_name":"Shire","has_results":true},{"nct_id":"NCT03888755","title":"A Study of Icatibant for Acute Attacks of Hereditary Angioedema in Japanese Participants","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":8,"lead_sponsor_name":"Shire","has_results":true},{"nct_id":"NCT02865720","title":"Study of C1 Inhibitor (Human) for the Prevention of Angioedema Attacks and Treatment of Breakthrough Attacks in Japanese Subjects With Hereditary Angioedema (HAE)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":8,"lead_sponsor_name":"Shire","has_results":true},{"nct_id":"NCT07290855","title":"A Study to Evaluate the Safety and Efficacy of Icatibant in Patients With Bradykinin Induced Angioedema","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":5,"lead_sponsor_name":"Nang Kuang Pharmaceutical Co., Ltd.","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}